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Abstract: Since their characterization more than five decades ago, gap junctions and their structural
proteins—the connexins—have been associated with cancer cell growth. During that period,
the accumulation of data and molecular knowledge about this association revealed an apparent
contradictory relationship between them and cancer. It appeared that if gap junctions or connexins
can down regulate cancer cell growth they can be also implied in the migration, invasion and
metastatic dissemination of cancer cells. Interestingly, in all these situations, connexins seem to be
involved through various mechanisms in which they can act either as gap-junctional intercellular
communication mediators, modulators of signalling pathways through their interactome, or as
hemichannels, which mediate autocrine/paracrine communication. This complex involvement of
connexins in cancer progression is even more complicated by the fact that their hemichannel function
may overlap with other gap junction-related proteins, the pannexins. Despite this complexity, the
possible involvements of connexins and pannexins in cancer progression and the elucidation of the
mechanisms they control may lead to use them as new targets to control cancer progression. In this
review, the involvements of connexins and pannexins in these different topics (cancer cell growth,
invasion/metastasis process, possible cancer therapeutic targets) are discussed.
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1. Introduction
The majority of cancers in adults are solid tumours [1]. Whatever their tissue origin, those tumours
are characterized by two fundamental properties, which are, first, an uncontrolled cell proliferation
forming the tumour itself and then an acquired invasion capacity leading to the dissemination of
cancer cells in the organism. Fifty years of investigation have shown involvement of gap junctions
(GJs) or their molecular components, the connexins (Cxs), in these two fundamental characteristics of
cancer progression [2–4]. More recently, it appeared that the involvement of Cxs could be complicated
by the fact that they can act independently from the establishment of gap-junctional intercellular
communication (GJIC). For instance, Cxs may be involved in these mechanisms through their
interactome to modulate signalling pathways [5] or by acting as hemichannels (Hcs) mediating
autocrine/paracrine communication [6]. This last activity may overlap with pannexins (Panxs) which
are Cx-related proteins (Figure 1) [7].
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Figure 1. Connexin and pannexin molecules and channels formed by these molecules. As molecules, 
connexins (Cx) and pannexins (Panx) have similar topology with four transmembrane and 
intracellular (Intra.) NH2 and COOH domains. In the left panels, both kinds of molecules are shown 
in a “spread” way to distinguish their topology (1) and in a “condensed” way (2) to better represent 
as transmembrane subunits of channels (centre panels) and gap junctions (right panel). In humans, 
21 subtypes of connexins have been characterized, which are differentially expressed in tissues [8]. 
They are named according to their expected molecular weight (kDa) from the smallest connexin 
(Cx23: 23 kDa) to the largest one (Cx62: 62 kDa). The best-known member of the connexin family is 
the connexin43 (Cx43) which is the most common in the organism. Only 3 pannexin subtypes are 
known in human (PANX1, PANX2, PANX3) [9,10]. Except for Cx26, connexins can be 
phosphorylated mostly at their intracellular COOH tail (red spots) [11]. The level of phosphorylation 
potentially modifies channel gating, interaction with intracellular or other membrane proteins 
(connexin interactome) and thus their function and life cycle [11,12]. So far, pannexins do not appear 
to be regulated by phosphorylation as connexins are but they are more characterized as potentially 
N-glycosylated (green spots) molecules at their extracellular (Extra.) domain. Both connexins and 
pannexins can aggregate to form hexameric transmembrane channels permitting the passive passage 
of ions (e.g., Ca2+) and small (<1–1.5 kDa) hydrophilic molecules such as nutrients (e.g., glucose: Glu), 
amino acids (e.g., glutamate: Glut), nucleotides (e.g., ATP) and second messengers (e.g., cAMP and 
IP3). Theoretically, connexin-made channels (connexons also called hemichannels) and 
pannexin-made channels (pannexons) are permeable to the same type of ions and molecules even if 
pannexons permeability has been mostly studied for ATP, Ca2+ and glutamate (Glut). Moreover, 
connexons from one cell can dock with connexons of juxtaposed cells forming intercellular channels 
aggregated in gap junctions which permit the direct intercellular transfer from cytosol to cytosol 
(gap-junctional intercellular communication, GJIC) of same ions and molecules as isolated 
connexons. So far, no pannexon-made gap junctions have been described in 
physiological/pathological conditions. The term connexon is mostly used to define the 
transmembrane unit of gap junctions. When isolated in the plasma membrane, connexons are 
usually called hemichannels and can open with various stimuli such as, for example, hypoxia. For 
clarity in the figure, putative phosphorylation sites (red spots) and N-glycosylated sites (green spots) 
are not shown in channels and gap junctions. 
Figure 1. Connexin and pannexin molecules and channels formed by these molecules. As molecules,
connexins (Cx) and pannexins (Panx) have similar topology with four transmembrane and intracellular
(Intra.) NH2 and COOH domains. In the left panels, both kinds of molecules are shown in a “spread”
way to distinguish their topology (1) and in a “condensed” way (2) to better represent as transmembrane
subunits of channels (centre panels) and gap junctions (right panel). In humans, 21 subtypes of
connexins have been characterized, which are differentially expressed in tissues [8]. They are named
according to their expected molecular weight (kDa) from the smallest connexin (Cx23: 23 kDa) to the
largest one (Cx62: 62 kDa). The best-known member of the connexin family is the connexin43 (Cx43)
which is the most common in the organism. Only 3 pannexin subtypes are known in human (PANX1,
PANX2, PANX3) [9,10]. Except for Cx26, connexins can be phosphorylated mostly at their intracellular
COOH tail (red spots) [11]. The level of phosphorylation potentially modifies channel gating, interaction
with intracellular or other membrane proteins (connexin interactome) and thus their function and life
cycle [11,12]. So far, pannexins do not appear to be regulated by phosphorylation as connexins are but
they are more characterized as potentially N-glycosylated (green spots) molecules at their extracellular
(Extra.) domain. Both connexins and pannexins can aggregate to form hexameric transmembrane
channels permitting the passive passage of ions (e.g., Ca2+) and small (<1–1.5 kDa) hydrophilic
molecules such as utrients (e.g., glucose: Glu), amino acids (e.g., glutamate: Glut), nucleotides
(e.g., ATP) and second essengers (e.g., cAMP and IP3). Theoretically, con exin-made channels
(connexons also called hemichannels) and pannexin-made channels (pannexons) are permeable to
the same type of io s and molecule ev n if pannexons permeability has bee mostly studied for
ATP, Ca2+ and glutamate (Glut). Moreover, connex ns from one cell can dock with connexons of
juxtaposed cells forming intercellular cha ls aggregated in gap junctions which p rmit the dir ct
inte cellular transfer from cytosol to cytosol (gap-junctional intercellular communicati n, GJIC) f
same io s and molecules as isolated connex s. So far, no p nnexo -m de gap junctions have be n
described in physiological/pathological conditions. The term c nexon is mostly use to define the
tran membr ne unit f g p junctions. When isolated in the plasma me brane, connexons are usually
called he ichannels and c n open with various stimuli such as, for example, hypoxia. For clarity in
the figure, putative p osphorylation sites (red spots) and N-glycosylated sites (green spots) are n t
shown c annels and gap junctions.
Int. J. Mol. Sci. 2018, 19, 1645 3 of 27
Possible involvements of Cxs and Panxs in cancer progression and the elucidation of the
mechanisms they control lead to their use as new possible targets to control cancer progression [13,14].
Here, we will review the involvement of Cxs and Panxs in these different topics, which are cancer cell
proliferation, invasion/metastasis process and as possible targets for cancer control.
2. Connexins and Pannexins Involvement in Tumour Cell Growth
2.1. Connexins Involvement in Tumour Cell Growth
Shortly after their characterization, GJs were thought to be involved in growth regulation [15].
This assumption was the consequence of the possibility to estimate GJ functions through electrical
coupling or diffusion of small hydrophilic fluorescent tracers [16,17]. By using such approaches, it
rapidly appeared that cells derived from solid tumours (hepatoma, thyroid tumours, etc.) were not
able to communicate through GJs [18,19]. These seminal studies introduced the notion that lack of
GJ coupling could be a fundamental process in cancer leading to the formation of solid tumours by
uncontrolled cell growth [15]. In other terms, growth regulation was the very first physiological role
attributed to GJs and their mediation of a direct intercellular communication.
During the following decades, the involvement of GJIC in cancer cell growth regulation has been
supported by a wide range of data. An early observation was about tumour promoter agents acting as
inhibitors of GJIC [20,21]. This was observed in several models and reinforced the parallel between
decreased GJIC and increased cell growth [22,23]. This parallel was extended to all kinds of phenomena
able to inhibit GJIC such as cancer-causing viruses [24]. And such a phenomenon was so widely
observed that it has been proposed that any GJIC inhibitor could be a potential tumour promoter [25].
If the tumour promoting effects of these chemicals were mostly known from in vitro studies, in some
cases, GJIC inhibition effect could also be observed in vivo with transgenic mice exhibiting higher
tumour susceptibility when defective for specific Cxs [26,27]. One of these best examples is liver
since Cx32 gene knockout (KO) mice were shown to be more susceptible than wild-type mice to liver
carcinogenesis after chemical treatments or even spontaneously [26]. This example was relevant to
rodent and human situations for which liver tumours were correlated with lack of GJIC either by loss
of expression or aberrant cytoplasmic localization of Cx32, respectively [28,29].
Conversely, strategies permitting the recovery of GJIC, by increasing Cx expression from
non-communicating cancer cells, were expected to decrease cell growth. And indeed, globally this was
the case as shown by approaches using chemical treatments or cDNA transfection. Chemicals known
to be putative chemopreventing agents (flavonoids, carotenoids, retinoic acids, etc.) appeared to act
on transformed cell lines by inducing GJIC and decreasing cell growth [30,31]. Cx cDNA transfection
in GJIC-defective cancer cell lines brought similar conclusions that Cx expression is accompanied
by decreased cell growth. This was observed in a variety of cancer cells (hepatoma, glioma, breast,
etc.) in vitro and in vivo [32]. However, the type of transfected Cx was important since such an effect
was mostly observed when the Cx of the normal tissue (before transformation or cancer progression)
was re-expressed [33,34]. These results suggested that a recovery of GJIC is not sufficient by itself to
have tumour suppressive effects but should be specifically controlled by the Cx subtype depending
probably on the permeability capacity of the GJ it forms.
Thus, significant data accumulated over 50 years supported a similar conclusion. Whatever the
models or the approaches (in situ detection of Cxs in tumours, cancer cell lines, chemical treatments,
transgenic mice, cDNA transfection, etc.), the global conclusion is that Cx expression/GJIC is inversely
correlated to cell growth. All these data have been analysed and synthesized in many reviews during
past decades [2–4,32]. By considering all these observations, two kinds of molecular mechanisms can
explain the involvement of Cxs in tumour cell growth regulation. The first one is to describe how Cxs,
when present, can control cell growth. The second kind of molecular mechanisms, which are also
needed for explaining the link between Cxs and cell growth, has to elucidate the origin of the lack of
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Cx expression or function which is observed in tumour cells. These are the two kinds of mechanisms
that will be reviewed below.
2.1.1. How Can the Presence of Connexins Regulate Cell Growth?
Most data attempting to elucidate how Cxs control cell growth came from Cx cDNA transfection
in cancer cell lines. And from such approaches, whatever the cell types which were used (osteosarcoma,
liver or lung carcinoma cells, etc.), a constant observation was that the increased expression of the
original Cxs was followed by a longer G1 cell cycle phase slowing down the cell proliferation rate
(Figure 2). A global analysis of these results suggests that this effect was the consequence of p27
accumulation [35,36]. From this common fact, diverse observations were made such as inhibition of
enzymatic activity of Cyclin-dependent kinases (CDK) [36] and decreased amount of Cyclin D1 [37]
and S-phase kinase-associated protein 2 (Skp2) [36,38,39]. To our knowledge, so far, no direct molecular
link between Cx presence and the regulation of cell cycle has been demonstrated. Besides such an
effect of Cxs on nuclear regulation of the cell cycle, it has been shown that Cxs can also act on the level
of expression of growth factors. For instance, Cx43 re-expression but not Cx32, in C6 glioma cells is
related to a decreased amount of milk fat globule-EGF factor 8 (MFG-E8) mRNA through an unknown
mechanism (Figure 2) [40]. Therefore, Cx expression is mostly related to change of expression of
growth factors or/and cell cycle regulators (p27, Cyclin D1, etc.). The most obvious scenarios for
explaining how Cxs, when localized at the plasma membrane, can control gene expression might
be through two major pathways. A first one would be through the Cx interactome by controlling
growth transduction signalling and the second would be by diffusing growth regulators through GJs.
Interestingly, as reported in the literature, both mechanisms have been observed and can explain the
specificity of cell growth control induced by Cxs.
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Figure 2. Connexin-mediated negative control of cell proliferation. Cx43 negatively regulates cell
growth by acting differently on activators (red) and inhibitors (blue) of cell proliferation. This regulation
is mediated through various mechanisms in which Cx43 acts by itself (1), as a sequestrator (2) of growth
regulators (e.g., CCN3, PTEN, Csk, c-Src), as a mediator of GJIC (3), through hemichannel activity (4)
or its 20 kDa carboxyl tail (CT)-domain (5). These various mechanisms act on the nucleus (thick black
arrows) to decrease cell proliferation. Some of these mechanisms are mediated by hemichannel or
gap-junction permeability (thick blue arrows). Positive (+)/negative (−) effects of Cx43 n cell cycle
regulators (p27, Cyclin D1, etc.) and c-Src effect on Cx43 are also shown (thin blue arrows).
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Gap-Junctional Intercellular Communication and Cell Growth Control
As mentioned above, the effect of Cx43 and Cx32 on cell growth has been extensively studied
through various experimental models (cDNA transfection, transgenic mice, etc.) and appears to be
specific. This specificity can be explained by their differential permeability which is illustrated
by adenosine whose permeability is shifted from Cx32 to Cx43 channels by adding phosphate
residues [41]. From such an observation, Cx channels appear as putative filters of intercellular
signals that can be the consequence of the channel itself (diameter, amino-acid composition) or
the configuration of the carboxyl tail (CT) which is sensitive to phosphorylation such as Cx43
channels closed by Src activation [42]. To our knowledge, a direct link between GJIC and growth
regulation can be found in three situations. The first one is about the osteoblastic model in which
extracellular growth stimulation induces the synthesis of second messengers that transit through
GJs to activate extracellular signal-regulated kinase (ERK) and phosphatidylinositol-4,5-bisphosphate
3-kinase (PI3)/Akt serine/threonine kinase 1 (Akt) pathways. The translocation of ERK into the
nucleus activates transcription factors that recognize a Cx-response element (CxRE) and induce
osteocalcin and collagen I-1 expression [43]. Another example finally could explain the specific tumour
suppressor effect of Cx26 on HeLa cells that was described two decades ago [33]. This effect seems to
be the consequence of the maintenance of Cx26-mediated GJIC during the G2/M phase which permits
intercellular cyclic 3′,5′-adenosine monophosphate (cAMP) redistribution able to delay the cell cycle
progression (Figure 2) [44]. And more recently, it was shown that not only metabolites like cAMP
could act as growth regulators passing through GJIC but also microRNAs (miRNAs) (Figure 2). As an
example, the transmission of anti-proliferative effects from miR-124-3p-transfected to non-transfected
glioma cells was mediated by GJIC [45]. Similarly, GJIC was shown to inhibit cancer cell growth
by transferring miRNAs from endothelial cells in vitro [46]. And interestingly, it was observed that
miRNA transfer can occur also by delivering from exosomes in which Cx43 facilitates the release of
content into target cells [47].
Cell Growth Control Independent from Gap-Junctional Intercellular Communication
The specific effect of Cxs in cell growth control can come also from their cytoplasmic domains
(internal loop and CT domain) which are unique in length and amino-acid sequences [8]. It has been
known for a long time that these parts and in particular the CT domain, can interact directly with
cytosolic/membrane proteins. Such interactomes have been mostly described for Cx43 for which
about 40 different proteins have been identified as interacting ones [12,48]. From such observations, it
became clear that the interactome may participate both to cell growth regulation by controlling channel
permeability (i.e., channel closure due to Src-induced tyrosine phosphorylation of the Cx43 CT domain)
or by modulating signalling pathways from the plasma membrane to the nucleus. For this last case, it
has been postulated that the CT domain of Cxs could control, through sequestration, the translocation
of putative transcription factors from the cytosol to the nucleus (Figure 2). Such a behaviour has been
described for Cx32 with Discs large homolog 1 (hDlg1) in hepatocytes [49] and for Cx43 with CCN3 in
rat C6 glioma cells [50,51]. In this last case, down regulation of Cx43 permits the translocation of CCN3
to the nucleus which activates cell growth (Figure 2) [50]. Such a situation can explain why glioma
cell growth is higher when Cx43 expression is repressed and vice-versa. A similar situation has been
shown for the transcription factor ZO-1–associated nucleic acid–binding protein (ZONAB) [52]. More
recently, the tumour suppressive effect of Cx43 expression could be explained by the region 266–283 in
the CT domain of Cx43 which is able to recruit PTEN and C-Terminal src kinase (Csk) to inhibit the
oncogenic activity of c-Src (Figure 2) [53]. It is also possible that such a phenomenon could still happen
when Cx43 is localized in the cytoplasm. Even if it has not been described yet, it would explain the
down regulation of growth which was observed in human glioblastoma cells after transfection of Cx43
which was mainly localized in the cytoplasm [54].
In this last example, Cx43 signal was also detected in the nucleus of the cells [54].
The anti-proliferative effect associated with a nuclear signal of Cx43 is more intriguing. This effect
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could be due to the Cx43 CT domain since the transfection of that part only was followed by decreased
growth in several cell types (HeLa, Neuro2a and HEK293 cells) [55–57]. It has been suggested that
the Cx43 CT domain would then act as a transcription factor but this hypothesis has not been proven
yet (Figure 2). However, a 20 kDa isoform which corresponds to the Cx43 CT domain is known to be
translated in some cell types under certain conditions activated in cancer cells and hypoxia [58]. Its
function is not known yet even if it has been shown to act as a chaperone protein for trafficking of
Cx43 to the cell membrane [59] and for microtubule dependent mitochondrial transport [60].
Finally, to be complete, Cxs are known to form Hcs in the plasma membrane (Figure 1) [61].
Study of those Hcs has been growing this last decade, especially for Cx43 but their link with cell
proliferation is still not obvious even if adenosine triphosphate (ATP) release and modulation of Ca2+
concentrations were correlated with decreased cell proliferation in several cell types [62]. In osteocytes,
they have been found to be involved in suppression of breast cancer cell growth and bone metastasis
using transgenic mouse models expressing dominant-negative mutants inhibiting either GJIC and/or
Hcs [63]. With recent development of new research tools, such as Cx-interacting peptides, antibodies
and dominant-negative mutants, the distinctive mechanisms of GJs versus Hcs, although still limited
start to be elucidated. However, the action of Cx Hcs can still be confounded with Panx channels
(Figure 1).
2.1.2. What Does Prevent Connexin Expression or Function during Tumour Progression?
The expression of Cxs is often decreased in tumours whatever their origin [32]. Such a decreased
expression may then participate to increase tumour growth by preventing the molecular mechanisms
controlled by the presence of Cxs that were reviewed in the previous section. The molecular events
leading to the disappearance of Cxs are not known precisely but could come from two mechanisms
acting either at the transcriptional or at the post-transcriptional levels of Cx expression.
At the transcriptional level, similar to other genes which are shut down during tumour
progression, Cx genes could be the target of epigenetic control. However, data about such a
transcriptional control of Cx expression are not abundant in the cancer context even if it was suggested
two decades ago [64]. In HeLa cells, silencing of the Cx43 gene was thought to be controlled by DNA
methylation [65]. Loss of Cx32 function through hypermethylation is necessary for the development
of renal cell carcinoma at the early carcinogenic process [66,67]. The CpG island hypermethylation
level was associated with heavy smoking, poorly-differentiated tumour and low expression of Cx43 in
non-small cell lung cancer [68]. More recently, hypermethylation of the Cx45 gene has been linked to
its reduced expression in colon cancer [69]. This field of research is probably under investigated and
would reveal if pursued that epigenetic phenomena are more involved than expected in the control of
Cx expression.
At the post transcriptional level, Cx function can be regulated by ubiquitination, glycosylation,
S-nitrosylation and in particular, phosphorylation of the CT domain. This has been mostly studied
for Cx43 whose phosphorylation regulates GJIC through different mechanisms such as Cx trafficking,
connexon assembly, channel gating and GJ degradation [11]. And indeed, in the cancer context, many
oncogenes encode for kinases (i.e., c-Src) or proteins activating kinases (growth factor receptors) that are
known to phosphorylate Cx43 and modulate its function [70]. As an example among others, epidermal
growth factor (EGF) inhibits GJIC by inducing mitogen-activated protein kinase (MAPK)-mediated
phosphorylation of Cx43 [71,72]. A similar effect has been observed for platelet-derived growth factor
(PDGF) which activates MAPK and protein kinase C (PKC) pathways [73]. Interestingly, such a
phosphorylation of the Cx43 CT domain establishes a direct link between growth stimulation and GJIC
inhibition, which appears to be either the consequence of channel gating or Cx degradation [74].
Still at the post transcriptional level, an emerging field is about repression of Cx expression by
miRNAs. For instance, mi-R-221/222 complex and miR-125b have been shown to downregulate Cx43
expression in glioma [75,76] or miR-20a in prostate cancer [77]. This field is still emerging and no
doubt that it will be more involved in Cx gene regulation in future years.
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Finally, the lack of expression or function of Cxs could be also theoretically the consequence of
mutations affecting either the coding region of the Cx genes or their promoters. However, contrary
to classical tumour suppressors (p53, Rb, etc.), such mutations have been rarely reported in the
cancer context [32]. The most convincing result revealed a mutation affecting the Cx43 CT domain
in human colon adenocarcinomas, which resulted in a restricted expression in invasive parts of the
tumours [78]. To our knowledge, such an observation has not been confirmed. The fact that Cx
mutations are not involved in human cancer is intriguing when considering their involvement in
several human hereditary diseases [79]. So far, none of these diseases are known to be associated
with a particular cancer susceptibility except for Cx26 mutations in the case of keratitis ichthyosis
deafness (KID) syndrome which are associated with squamous cell carcinomas in 15% of patients [79].
The apparent general lack of association with cancer is probably the consequence of a lack of follow up
of such patients.
2.2. Pannexins Involvement in Tumour Cell Growth
Originally, Panxs (3 members in mammals: Panxs1, 2 and 3) were identified as GJ proteins
exhibiting homology with the invertebrate GJ proteins, the innexins [9]. Present in chordates, contrary
to Cxs and despite a similar topology, they are not able to form functional GJs but form single
membrane channels releasing autocrine and paracrine signals similar to Cx Hcs [10].
Data about a possible relationship between Panx expression and cancer progression or cancer cell
growth are not so developed as they are for Cxs. In general, it seems that Panxs exhibit a so-called
tumour suppressive effect similar to what is observed with Cxs. Such an analogy started during
the last decade with the analysis of the brain cancer gene expression database REMBRANDT which
revealed that the expression level of PANX2 and also PANX1 is positively correlated to post diagnosis
survival of glioma patients [80]. To some extent, these observations were confirmed by the tumour
suppressive effect induced both by Panx1 and Panx2 overexpression in rat C6 glioma cells in vitro and
in vivo conditions [81,82]. In those cells, Panx1 expression had a wide range of anti-tumour activity by
reducing in vitro cell proliferation, cell motility, anchorage-independent growth and tumour growth
in nude mice. Interestingly, these effects, which are globally similar (except cell motility) with those
observed after Cx43 transfection, were accompanied by an increased GJIC [81].
Similar observations have been obtained from skin where PANX1 and PANX3 levels are reduced
both in human keratinocyte-derived basal cell carcinomas and squamous cell carcinomas [83].
This is in line with studies showing that those Panxs reduce growth of rat epidermal keratinocytes
when overexpressed [84]. Such a growth inhibition was also observed for Panx3 in chondrocytes
and osteoprogenitor cells by inhibiting the WNT pathway and via calcium-mediated regulation
of p21 [85,86]. Recently, Panx3 was shown to inhibit the odontoblast proliferation through
AMP-activated protein kinase (AMPK)/p21 signalling pathway and promote cell differentiation
by bone morphogenetic protein (BMP)/Smad signalling pathway [87].
However, the situation is not so clear and probably depends on the cell type by considering
melanocytes in which Panx1 expression is low whereas increased expression is correlated with
melanoma aggressiveness [88]. More data are necessary before understanding the real involvement of
Panxs in cancer cell growth control.
3. Connexins and Pannexins: Involvement in Tumour Metastasis and Microenvironment
3.1. The Process of Metastasis
In order to become metastatic, a clone of cancer cells must acquire aggressive growth properties
and/or stem cell-like properties and the tumour microenvironment can drive acquisition of migratory
and invasive properties through epithelial to mesenchymal transition (EMT). In the majority of
tumours, which are epithelial in origin, cells must be able to breach the basement membrane, invade
into the stroma and into blood vessels (intravasation) that infiltrate the tumour site. In the vasculature,
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they will adhere to blood vessel walls and be transported to distant sites where they emerge from
the circulation (extravasation) to initiated new tumours. Finally, establishment of metastatic tumours
requires survival and growth in the new tissue microenvironment. During all of these processes
metastatic cells must evade the anti-tumoral immune response (Figure 3).
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Table 1. Selected representative examples of changes in connexins during tumour progression and metastasis.
TISSUE ORGANISM CONNEXIN REGULATION REFERENCE
PRECANCERS AND PRIMARY TUMOURS
PANCREATIC DUCTAL
ADENOCARCINOMA Mouse Cx43
Increased levels
Changes in
phosphorylation
[89]
CERVICAL CANCER Human Cx26, Cx30, Cx43 Loss of connexinexpression [95–97]
BREAST CANCER Human Cx26, Cx43 Loss of Cx43 gapjunctions [98–101]
PROSTATE CANCER Human Cx32, Cx43 Decreased expression [102]
COLON CANCER Human Cx32, Cx43 Gradual loss ofexpression [92]
MELANOMA Human Cx26, Cx30 Increased expression [103]
PRIMARY TUMOUR TOMETASTASIS
BREAST CANCER Human Cx26, Cx43 [101,104–108]
BRAIN Human, ratHuman
Cx30
Cx43 Reduced expression
[109]
[110,111]
PROSTATE Human cell lines Cx43
Increased Cx43
associated with
increased invasion
[112]
LIVER Rat cell linesHuman
Cx43
Cx26
Cx43 overexpression
High expression
[113]
[114]
MELANOMA HumanHuman cell lines Cx26 Increased expression
[103,115]
[116]
3.2.2. Invasion and the Local Microenvironment
E-cadherin is required for invasion in EMT and its loss is a marker of tumour progression. During
invasion, cells display decreased GJIC, modification of cell-matrix interactions and acquisition of
proteolytic properties to degrade the basal laminal proteins. Following this, altered stromal cells
and microenvironment facilitate the motility of invasive cells through the extracellular matrix. All of
these processes could be potentially altered by changes in Cx expression. For example, transfection of
poorly coupled mouse epidermal cells with an E-cadherin expression construct increased GJIC [117].
Conversely, in prostate cancer cells, Cx43 levels correlated with levels of the transcription factor Snail-1
that inhibits expression of E-cadherin to promote EMT [118]. High levels of Cx43 and Snail-1 resulted
in increased tumour cell invasion and Cx43 was downregulated upon Snail-1 silencing and vice
versa. In keeping with these findings of a Cx43-Snail-1 axis controlling tumour cell behaviour, Cx43
expression could reverse A549 lung tumour cell resistance to the chemotherapeutic drug cisplatin by
downregulating E-cadherin and EMT, while siRNA depletion of Cx43 initiated EMT [119]. Melanoma,
breast, prostate and gastric cancers all display upregulated Cx43 and Cx26 in invasive lesions and
metastases (Table 1) [101,103,104,112,115].
3.2.3. Promoting Metastasis: Connexins and Cell Motility
Early studies revealed that HeLa cervical cancer cells overexpressing Cx43 gained invasive
properties in a chicken heart spheroid assay [120]. In a mouse melanoma model of metastasis
following subcutaneous injection, clone F10 was less metastatic than the high Cx26-expressing clone
BL6 but became as metastatic as BL6 upon Cx26 overexpression and BL6 cells expressing dominant
negative Cx26 showed reduced metastatic potential [116]. γ-irradiation of C6 glioma cells induced
Cx43 expression and increased ERK signalling and cell migration and a high Cx43 expressing clone
displayed increased motility and invasion [121]. Conversely, knocking down Cx43 abrogated p38
MAPK activation and radiation-induced C6 cell migration [122]. Although GJIC was decreased upon
Cx43 small interfering RNA (siRNA) depletion in the high Cx43 expressing C6 cells, GJ inhibitors
did not alter motility indicating that Cx43 itself was responsible for the pro-metastatic effects [121].
Similarly, in a six-cell model of hepatocellular carcinoma, following injection into the tail vein of
mice, only those lines with high metastatic potential formed foci in the lungs of the animals and this
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was reversible by depletion of Cx43 expression [113]. Another study found that blocking GJIC in
GL15 glioblastoma cells increased motility in an in vitro 3D culture model [123]. However, blocking
heterologous GJIC in ex vivo brain tissue by carbenoxolone reduced cell migration [123].
Cxs can facilitate adhesion of migrating cells to the endothelial layer of blood vessels and/or to
specific distal sites (Figure 3). For instance, metastatic lung cancer cells could adhere to endothelial
cells through GJs [124] as could metastasis-enabled melanoma cells ectopically expressing Cx26 in
in vitro cultured vein segments [116]. In the case of colon cancer cells, conditioned medium from
primary tumour cells enhanced phosphorylation of Cx43 and GJ formation between tumour and
endothelial cells via the molecular chaperone heat shock protein 27 (HSP27), while metastatic colon
cancer cells induced expression of Cx32 through action of the chemokine receptor CXCR2 [125]. Breast
cancer cells that formed functional Cx43 GJs with endothelial cells facilitated migration out of the
endothelial layer in in vitro culture [126] implicating Cx43 in the extravasation phase of metastasis.
In zebrafish and chick embryo models, breast cancer and melanoma cell metastasis was dependent
upon Cx43 and Cx26 to initiate brain metastatic lesions in association with the vasculature. Inhibition
of Cx43-mediated GJIC inhibited extravasation, as did knock down of the EMT transcription factor
twist [127].
3.2.4. Involvement of Gap Junctions and Hemichannels in Metastasis
Apparently contradictory effects of Cx43 in metastasis have been observed in different studies.
When a functional null mutant Cx43 mouse line (G60S: that also has dominant negative effects on
endogenous Cx43 activity) was crossed with erythroblastic leukemia viral oncogene homologue (ErbB)
overexpressing mice [128], there was delayed onset and fewer and smaller primary breast tumours
than in wild type mice but increased metastases to the lung [128]. In contrast, Cx43 overexpression in
highly metastatic lung cancer cells reversed the metastatic tumour phenotype [129] but decreased Cx43
gene expression yielded breast cancer cells with increased metastatic potential [130,131]. In a two-cell
model of prostate cancer, overexpressed Cx43 was present only in the cytoplasm and repressed
proliferation, adhesion and invasion of normally invasive PC-3 cells. In contrast, overexpression
of Cx43 in poorly metastatic LNCaP cells, re-established GJIC and increased bone metastasis in
mice [132]. Stable overexpression of Cx43 in the MDA-MB-435 breast cancer cell line did not alter
GJIC, invasion or migration in vitro. However, when injected into mice, the cells exhibited a reduced
growth rate and fewer lung metastases [106]. This phenomenon was found to be GJIC-independent
and it was suggested that it could be related to reduced N-cadherin expression, which would inhibit
EMT. In another study, GJIC was restored in the same metastatic breast cancer cell line upon ectopic
expression of the breast cancer metastasis suppressor gene BRMS1 [130]. The BRMS1-expressing
cells showed increased levels of Cx43 but reduced Cx32, leading to loss of GJIC between breast
cancer cells and between them and breast epithelial cells [130]. An in vivo murine study revealed
that metastatic breast cancer cells in the bone formed more active GJs with osteoblasts than with
themselves and BRMS1 expression increased homotypic GJIC. The breast cancer cells with increased
heterotypic, relative to homotypic, GJ channels with osteoblasts were more metastatic than those
that did not [105]. This suggests that the relative percentage of homo- and heterotypic GJ channels
in tumour cells can influence metastasis. Moreover, it suggests that heterotypic GJs could be an
important survival mechanism of tumour cells in the metastatic tumour microenvironment. It can be
concluded that the precise timing of elevated or reduced Cx expression could be key to any effects
during tumour progression.
Compared to GJs changes in Hc activity can produce different effects in metastasizing tumour
cells. In a bone metastatic clone of MDA-MB-231 breast cancer cells, decreased Cx26 and Cx43 levels
correlated with metastatic potential partly through alterations in Hc activity [107]. Similarly, a recent
study reported suppression of breast cancer cell metastasis to the bone through osteocytic Cx43
Hcs [63]. Drug or mechanically-induced opening of Cx43 Hcs to release ATP from osteocytes led
to inhibition of invasion and migration of the cancer cells. Analysis of a dominant negative Cx43
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mutant that blocks GJs but not Hcs, revealed that Cx43 Hcs protected against tumour progression
and metastasis [63]. The precise role of Cxs in tumour progression and metastasis might depend
on the nature of the tumour, the properties of the cancer cell itself, the site of metastasis and the
possibility of forming functional GJs at that site. It is clear that the tumour microenvironment drives
cancer metastasis and Cx43 seems to stimulate growth of brain metastases after extravasation and
tumour vasculature remodelling [133]. Protocadherin 7, a brain-specific cadherin, promoted Cx43-GJ
assembly between breast and lung tumour cells and astrocytes. These GJs allowed cyclic guanosine
monophosphate (cGAMP) to activate the stimulator of interferon genes (STING) pathway in astrocytes
to induce an interferon response. The resulting changes in cell signalling could enhance growth of
metastatic cells [133].
3.2.5. The Tumour Microenvironment
The tumour microenvironment, whether at the primary or secondary sites, is key to tumour
cell survival and tumour progression [134]. In agreement with the hypothesis that Cxs control the
microenvironment, Cx43-transfected glioma cells, which formed GJs with astrocytes in the striata of
rats, were able to disseminate throughout the brain parenchyma. Cx43 itself, unlinked to GJIC, was
shown to induce adhesive properties in the malignant glioma cells, which formed aggregates and were
more invasive [135]. Also in rats, formation of GJIC with fibroblasts in co-culture stimulated prostate
cancer cell migration [136,137]. However, Cx32 expression in metastatic renal cancer cells caused
abrogation of invasive capacity via inactivation of c-Src signalling [138]. Tumour-associated immune
cells are components of the tumour microenvironment. Heterotypic Cx43-GJs between tumour cells
and dendritic cells can transmit melanoma antigenic peptides leading to activation of cytotoxic T-cells
in vitro [139]. In vivo demonstration of Cx43-GJ transmission of antigenic peptides between antigen
presenting cells has also been demonstrated [140]. GJ transmission of miRNAs between immune
cells in the microenvironment and tumour cells is also expected to be a major regulator of metastasis
because of the key role of many miRNAs in tumour suppression, while others can promote tumour
progression [141].
3.3. Pannexins and Metastasis
The potential role of Panxs in metastasis is relatively unexplored. However, high levels
of PANX1 mRNA were associated with metastatic spread in a two-cell model of hepatocellular
carcinoma [142]. A key advance in understanding the role of Panxs in metastasis came from a
study of the isogenic melanoma cell lines, F10 and BL6, mentioned previously. PANX1 levels were
greatest in the most metastatic BL6 line [88]. PANX1 knock down reverted BL6 cells to a more
normal melanocyte phenotype and these cells had reduced levels of vimentin and β-catenin, both
markers of melanoma progression [88]. Importantly, in vivo data in a chick embryo xenograft model
showed that reducing PANX1 expression reduced tumour growth and metastasis to the liver. A recent
RNASeq analysis of breast cancer cells with different metastatic capacities revealed that cell lines
with high metastatic potential had significantly enriched mutant mRNA encoding a N-terminal
truncated PANX1 channel [143]. Truncated PANX-1, in association with wild type PANX1, seemed
to confer a gain-of-function to channel activity and was found to promote metastatic cell survival.
This appeared to be due to protection of tumour cells exiting the microvasculature via restrictive spaces
between endothelial cells by enhancing ATP release from the Panx channels stimulated by mechanical
deformation and abrogation of cell death [143]. In melanomas, P2X7/PANX1 channel activity has been
linked to regulation of the NLRP3 inflammasome, which can result in release of pro-inflammatory,
tumour promoting cytokines. Downstream effects on the tumour microenvironment could stimulate
tumour growth and invasion. Of course, like Cxs, Panxs might also be found in future to repress
tumour progression and metastasis.
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4. Connexin and Pannexin Channels in Potential Cancer Therapeutics
4.1. Connexin Channels in Potential Cancer Therapeutics
The usefulness of Cxs and GJs as potential therapeutic targets for treating cancer has been studied
for over four decades [4,144,145]. In recent years, several approaches have been developed in animal
models to determine treatment modality by manipulating Cx channels. Although preclinical studies
targeting connexin channels are still in their infancy, they hold great promise as de novo targets for
cancer treatment.
4.1.1. Chemical Compounds in Modulating Connexins and Potential Cancer Therapy
Major attempts have focused on enhancement of GJIC function due to its impairment in primary
cancer cells. Multiple chemical compounds have been used (e.g., retinoids, vitamin D, carotenoids,
cAMP and lovastatin), which can fully or partially reverse the deficiency of GJIC in tumorigenic
cells [146]. Lypopene, a carotenoid stimulates GJIC and Cx43 expression and inhibits the growth
of the breast cancer MCF-7 cell line [147]. Extracts from the zooxanthellate jellyfish that show
antioxidant activity exhibit higher levels of GJIC and cytotoxicity in MCF-7 cells than human epidermal
keratinocytes [148].
An experimental approach was developed that killed tumorigenic cells based on GJIC selectively
formed between them. In this study, tumorigenic BALB/c 3T3 and rat liver cells were loaded with
Lucifer yellow (LY) and co-cultured with non-tumorigenic cells. By irradiation with blue light,
only tumorigenic cells containing LY died but not the surrounding non-tumorigenic cells without
LY [149]. This study further showed that when dibutyryl cAMP, retinoic acid, fluocinolone acetonide
or dexamethasone were used during cell transformation, there was a reduction of transformed
BALB/c 3T3 cell foci. These chemicals also increased and established GJIC between tumour cells and
surrounding non-tumour cells, suggesting that the effects of chemicals on reversing the phenotypes of
transformed cells rely on the establishment or enhancement of GJIC between tumour and normal cells.
Several cholesterol-lowering statin drugs (lovastatin, simvastatin, etc.) are suggested as anticancer
reagents and high levels of mevalonate production are documented in various types of malignancies.
Therefore, inhibition of the mevalonate producer, β-Hydroxy β-methylglutaryl-CoA (HMG-CoA)
reductase, by statins offers a great potential for cancer treatment [150]. An earlier study shows that
lovastatin increases GJIC in transformed E9 mouse lung carcinoma cells through the inhibition of PKC,
although Cx43 expression and phosphorylation are not affected [151]. Moreover, apigenin, a flavonoid
and lovastatin that is known to increase GJIC enhances bystander effect of the herpes simplex virus
thymidine kinase/ganciclovir with reduction of cancer cell recovery on MCA38 adenocarcinoma cells,
while neither chemical alone has such effect [152]. In vivo injection of both chemicals achieves 60–70%
complete remission of tumour implanted in mice [152]. Simvastatin induced up-regulation of GJIC in
Leydig tumour cells and this upregulation sensitized tumour cells to etoposide, a chemotherapeutic
drug [153]. Simvastatin inhibited Cx43 phosphorylation by PKC and enhanced Cx43 membrane
localization to promote formation of GJs (Ser368 phosphorylation promotes Cx43 internalization).
However, a follow up study by the same group reported a protective function of simvastatin against
toxicity by cisplatin on normal Sertoli cells [154]. This effect occurs at high cell density where GJIC
forms and decreased GJIC by inhibitors or knocking down Cx43 by siRNA attenuates cell protective
role of simvastatin. These two studies elucidate differential roles of GJIC by statins in chemotherapy
by sensitizing drug effect on cancer cells and ameliorating toxicity in normal cells.
For Cx43 Hcs in cancer development, carbon monoxide (CO), a promising molecule to treat
several diseases including cancer has been shown to inhibit their function [155]. CO donors inhibit
Hc uptake in tumour cell lines (MCF-7 and HeLa cells) expressing exogenous Cx43 or Cx46 [156].
However, in general, scarce information is currently available describing the involvement of Cx Hcs in
cancer cells.
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Cxs can directly mediate the effect of chemotherapeutic drugs on cytotoxicity and apoptosis
of cancer cells. Upregulation of Cx43 by cisplatin improves its resistance in a mesothelioma cell
line (H28) [157]. GJIC inhibition fails to abrogate this effect but it is Cx43-dependent through the
suppression of c-Src activation. Cx43 is increased in H28 cells by sunitinib treatment, which promotes
apoptosis via the inhibition of receptor tyrosine kinase (RTK) signalling. This effect is likely to be
mediated through direct interaction of Cx43 with an apoptotic related protein, Bax [158]. The Cx43
enhanced apoptotic effect of sunitinib was via enhancement of activation of Bax localized at the
mitochondrial membrane and the phosphorylation of c-Jun N-terminal kinase (JNK) [159]. Several
studies focus on the strategy of enhancing Cx expression in cancer cells. Ganoderma lucidum, an
herbal mushroom known to inhibit tumour growth can increase Cx43 expression as well as vascular
endothelial growth factor (VEGF) and inhibit growth of human ovarian cancer cells [160]. Such
effect was abrogated by knocking down Cx43 expression. The bioactive substance sulforaphane
inhibits cancer stem cells in aggressive pancreatic ductal adenocarcinoma through increased Cx43
and E-cadherin expression [161]. This treatment also inhibits the cancer stem cell markers c-Met and
CD133, alters activation of several kinases and substrates, Glycogen synthase kinase 3 (GSK3), JNK
and PKC and enhances GJ channels. Therefore, chemicals that can enhance GJs and Cx expression
exhibit a high potency in suppressing cancer cell proliferation and tumour growth.
4.1.2. Connexin-Targeting Strategies in Potential Cancer Therapy
In recent years, several Cx mimetic peptides that reproduced portions of Cx sequences have been
widely used in basic research as well as preclinical and therapeutic development [145]. Cx43-GJIC is
decreased in breast cancer cells and efforts have been made to restore GJIC in these cells. αCT1,
a mimetic peptide that targets CT domain of Cx43 can sustain and enhance GJIC function and
has shown a great promise in promoting wound healing in skin by reducing scar formation [162].
A recent study shows that this peptide enhances Cx43 GJIC and reduces proliferation or survival
of MCF7 and MDA-MB231 breast cancer cells but has no effect on MCF10A non-transformed
cells [163]. A combination of αCT1 with tamoxifen or lapatinib augmented their effects on oestrogen
receptor-positive MCF7 or Her2-positive BT474 breast cancer cells. Furthermore, treatment with
αCT1 peptide sensitized human O-6-methylguanine-DNA methyltransferase (MGMT)-deficient and
chemotherapeutic agent temozolomide (TMZ)-resistant glioblastoma (GBM) cells and combined
treatment with the peptide and TMZ further incur autophagy and apoptosis of TMZ-resistance GMB
cells [164]. A recent study shows that a cell-penetrating Cx mimetic peptide, TAT-Cx43(266-283) inhibits
c-Src and focal adhesion kinase (FAK), upregulates phosphatase and tensin homology and reduces
the growth, migration and survival of glioma stem cells (GSCs) from patients [165]. A Cx43 mimetic
peptide juxtamembrane 2 (JM2) that is based on the Cx43 microtubule-binding domain inhibits Cx43
trafficking to the cell surface by promoting microtubule polymerization and reduces Hc numbers in the
membrane for proinflammatory function. The authors imply that this peptide may have therapeutic
value in treating proliferative diseases and cancer [166]. However, it is important to note that the
recovery of GJIC does not consistently entail normalization of the tumour cells.
There are several reports concerning use of antibodies against Cxs. When a labelled monoclonal
antibody against the second Cx43 extracellular loop domain was intravenously injected into rats
with intracranial C6 glioma, antibody signals were detected in reactive, glial fibrillar acidic protein
(GFAP)-positive astrocytes [167]. PEGylated immunoliposomes carrying monoclonal antibodies
against GFAP and the above-described Cx43 monoclonal antibody were detected at the periphery
of the glioma using either fluorescent or a paramagnetic probe [168]. These studies imply that
these antibodies could potentially be used for targeted delivery of drugs to the zone of high-grade
gliomas. Furthermore, magnetic resonance imaging data show that weekly administration of this
Cx43 antibody at a dose of 5 mg/kg significantly reduces low-differentiated glioma volume and
increases lifespan with a full recovery without delayed relapses in 19% animals [169]. Both Cx43 and
brain-specific anion transporter (BSAT1) are preferably expressed in the brain tumour and peritumoral
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areas. Cisplatin-loaded nanogel conjugated with monoclonal Cx43 antibody [170] and BSAT1 was
used to treat rats bearing tumours and the median survival was greater than control groups [171].
Vector nanogels seemed to reduce systemic toxicity of cisplatin [170]. Intriguingly, a combination
of this Cx43 antibody with TMZ completely abolishes the antitumor effect of this antibody while
combination treatment with γ-irradiation greatly inhibits tumour development and prolongs survival
median to 60 days versus 38 days [172]. Recently, a magnetic resonance imaging (MRI) study further
shows that uptake of Gd-based contrast agent with the same monoclonal Cx43 antibody is more than 4
times higher than nonspecific IgG-contrast agent and this Cx43 antibody conjugated agent markedly
enhances visualization of glioma in vivo [173]. Although the specific molecular mechanism of this
antibody is unknown, this Cx43-targeting monoclonal antibody could be developed as a potential
drug and/or diagnostic agent for glioma therapies.
Finally, recombinant lentiviruses carrying siRNA were used to knockdown Cx37 expression
in subcutaneous gastric tumours in mice [174]. Reduced levels of Cx37 are associated with higher
apoptotic index of tumour cells in vivo. Cx46 is also detected in GBM cancer stem cells, while Cx43
is predominantly expressed in non-stem cells [175]. Besides Cx43, Cx46 is shown to express in
GBM cancer stem cells (CSCs) that forms GJIC, while Cx43 is present in non-CSCs. During cancer
differentiation, Cx46 is reduced associated with an increase of Cx43 and knocking down Cx46 by short
hairpin RNA (shRNA) reduces stem cell maintenance.
Drug resistance is a major challenge for cancer treatment. Cisplatin is a commonly used
chemotherapeutic agent for advanced non-small cell lung cancer but prolonged treatment leads
to resistance due to development of EMT [119]. Overexpression of Cx43 reverses EMT and cisplatin
resistance while Cx43 deletion initiates EMT and drug resistance in human lung cancer cell line A549.
Patients with GBM, an aggressive adult primary brain tumour with poor prognosis, develop resistance
to TMZ chemotherapy. In contrast to the situation in lung cancer, Cx43 is increased with the formation
of GJIC in the resistant tumour cells and this increase is induced by epidermal growth factor receptor
(EGFR) activated JNK-ERK1/2-AP-1 signalling [176]. Moreover, Cx43 expression in human glioma cells
enhances resistance to TMZ via a mitochondrial apoptosis pathway by the reduction in Bax/Bcl-2 ratio
and the release of cytochrome C [177]. Consistently, a recent study [178] showed that TMZ-resistant
subline of U251 human GBM cells exhibited elevated Cx43 level compared to parental U251 cells,
which was companied with increased EMT markers including vimentin, N-cadherin and β-catenin and
decreased cell migration, monocyte adhesion and levels of vascular cell adhesion molecule (VCAM)-1.
These studies suggest that depending upon cancer types, Cx43 expression and GJIC could be involved
in either promoting or inhibiting sensitization of resistant cells to the chemotherapy. However, the
underlying mechanisms remain elusive.
Recently, a new paradigm was proposed based on the data obtained in chronic inflammatory
disorders and trauma in the eye that protecting cancer vasculature leads to reduced tumour hypoxia
and promote survival of normal cells [179]. Given that Cx43 Hcs are involved in vascular leakage
and endothelial cell death [180], modulation of these channels may provide an alternative for cancer
treatment. Together, with advanced understanding of the mechanism of Cx channels in various types
and stages of cancer development and metastasis, new lines of drugs that target them in cancer therapy
are moving closer to reality.
4.2. Pannexin Channels in Potential Cancer Therapeutics
A great progress has been made in recent years for our understanding of Panx biology and
physiology. However, compared to that of Cxs, the potential therapeutic application of Panxs in cancer
is still limited.
4.2.1. Pannexin Channel Activation and Potential Cancer Therapy
Panx channels mediate ATP release and anti-tumour immune responses are associated with such
a release from apoptotic cancer cells to engage P2 purinergic receptor signalling in leukocytes. A study
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shows that apoptotic reagents activate Panx1 channels via caspase-3 cleavage, which leads to ATP
release in Jurkat T cell acute lymphocytes in chemotherapeutic drug-induced apoptosis [181,182]. Panx1
level is much higher in leukemic T lymphocytes than untransformed T lymphoblasts. Interestingly,
chemotherapeutic drugs also cause ATP release with inhibition of caspase activation, which implies
a Panx-independent mechanism. This study suggests that Panx1 channels and ATP release may
mediate paracrine interaction between dying tumour cells and leukocytes in anti-tumour responses.
A follow up study by the same group shows that activation of Panx1 channels by ATP is determined
by expression level of particular ectonnucleotidases in tumour cell variants in Jurkat cell lines with
and without the Fas-associated death domain (FADD) or receptor-interacting protein kinase 1 (RIP1)
cell death regulatory proteins [183]. They noticed that robust levels of extracellular ATP/AMP were
accumulated in apoptosis-deficient cells, not in apoptotic cells with the activation of Panx1 channels
in response to chemotherapeutic drugs. Panx1 channel assists in accumulating immune-stimulatory
ATP versus immunosuppressive adenosine within the tumour microenvironment. In support of the
role of ATP and Panx1 channels in mediating immune response, a very recent study shows that ATP
increases migration of dendritic cells through the activation of Panx1 channel and P2X7 receptor
(P2X7R) [183]. In this study, they show that ATP actives P2X7R, which leads to opening of Panx1
channels and consequently results in more ATP release, re-organization of the actin cytoskeleton and
faster migration of dendritic cells. Additionally, in vivo data show that Panx1 channels are required
for the homing of dendritic cells to lymph nodes but not for maturation. Therefore, given that ATP acts
as danger signal that recruits phagocytes including dendritic cells to cancer sites, activation of Panx
channels through therapeutic drugs could hinder tumour growth and metastasis. Moreover, an US
Food and Drug Administration (FDA)-approved anti-parasitic drug, Ivermectin allosterically regulates
P2X4 receptors in breast cancer cells through opening of the P2X4/P2X7-gated Panx1 channels, which is
associated with ATP release and consequently, cancer cell death [184]. Additionally, Ivermectin induces
activation of autophagy and enrichment of inflammation mediators, ATP and high-mobility-group B
(HMGB), suggesting that modulation of purinergic receptor signalling could be used as a platform for
cancer immunotherapy [185].
4.2.2. Pannexin in Potential Cancer Diagnosis
A clinical report shows high relative expression of Panx3 in a patient with primary cutaneous
sweat gland carcinomas with histologic features of a high-grade osteosarcoma [186]. By using
quantitative trait loci (QTL) analysis, sequence comparison between strains and gene network analysis,
this report links both body mass index (BMI) and tumorigenesis with Panx3 as a candidate gene in
a genetically heterogeneous mouse model with carcinogen-induced cancer. A mutation encoding a
truncated Panx1 (1–89) was identified which was enriched in highly metastatic breast cancer cells [143].
This truncated form of Panx1 further enhanced ATP release. In contrast to general belief of Panx
channels in promoting cancer cell death, this paper suggests that ATP release by Panx1 suppresses
deformation-induced apoptosis through P2Y receptor signalling and inhibition of Panx1 channels
could reduce the efficiency of breast cancer metastasis. This could be partially explained by excess
release of ATP by mutated Panx1 channels. Panx1 is present in skin melanocytes and is upregulated
during melanoma tumour progression and tumorigenesis [88]. Knockdown of Panx1 in tumour cells
decreases tumour cell growth, which indicates Panx1 as a potential target for treating melanoma.
More studies are required to assess the expression levels of Panx subtypes in various types and stages
of cancer.
4.2.3. Pannexin Channels in Pain Management Related to Cancer Treatment
Repeated treatment with the chemotherapeutic drug oxaliplatin is limited due to the development
of a neuropathic pain in cancer patients. Functional recruitment of Panx1 mediates the increase of
P2X7Rs in cerebrocortical nerve terminal in oxaliplatin-treated rats. Moreover, P2X7R antagonists and
Panx1 inhibitors, Erioglaucine and 10Panx peptide reverts neuropathic pain caused by oxaliplatin,
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while Panx1 inhibitors do not interfere the cytotoxic effect of oxaliplatin on human colon cancer cells
HT-29 [187]. Consistently, a recent study shows that Panx1 expressed in immune cells plays a critical
role for pain-like effects after nerve injury and this response is abrogated in Panx1 gene deficient
mice [188]. These studies suggest that therapeutic modulation of Panx1 could be useful for treating
neuropathic pain associated with cancer and cancer treatment.
5. Discussion and Conclusions
The involvement in cancer of GJs and their structural proteins, the Cxs, is a long story [4]. It rose
just after the discovery of these particular intercellular junctions, which appeared to be absent in cancer
cells. These very first observations suggested that the lack of GJIC could contribute to the lack of cell
growth control which characterizes tumorigenesis [18]. Therefore, cell growth control was assumed to
be one of the fundamental roles played by GJs. However, if this implication was assumed fifty years
ago, the precise molecular mechanisms controlling cell growth came very late and are still unclear.
There is a kind of paradox between the amount of observations accumulated for decades confirming
a possible role of GJs as guardians of cellular homeostasis and replication and the lack of sufficient
evidence explaining such a phenomenon.
Indeed, despite few exceptions, all kinds of observations were suggesting that the lack of GJs
or Cxs is correlated to the lack of cell growth control and vice versa This consensus was supported
by observations collected from a tremendous variety of models (cancer cell lines, primary cultures
of tumour cells, in situ from biopsies, Cx-cDNA transfected cells, Cx-KO mice, chemical treatments
decreasing or upregulating GJIC, etc.) whatever the species origins [32]. However, despite this
consensus of observations, the assumption that GJs and Cxs were so-called tumour suppressors
was not fully supported by several facts. First, GJs and Cxs did not behave as classical tumour
suppressors since Cx gene mutations never appeared in tumours as commonly shown as for p53,
Rb and so forth [32]. Second, no clear molecular mechanisms underlying the growth control that
GJs and Cxs could exert has been established contrary to what was observed with classical tumour
suppressors. These two aspects probably restricted GJs and Cxs to be considered as a real hallmark of
cancer despite all the consensus studies we mentioned above [189]. The few molecular mechanisms
that could explain the cell growth control exerted by GJs and Cxs seems to be “diffuse” and not so
straightforward as growth signalling pathways described for oncogenes and tumour suppressors.
Indeed, the involvement of Cxs in cell growth control is not clear at the molecular level and appears to
be either GJIC-dependent or not. When this involvement was found to depend on GJIC, Cxs permit the
intercellular diffusion of metabolites acting on cell growth control (i.e., Cx26 and the diffusion of cAMP,
all along the cell cycle phases in HeLa cells) [44]. When this growth control is GJIC-independent, Cxs
seem to act through their CT domain as a sequestrator preventing the nuclear translocation of cell
growth regulators [53]. By comparing to our knowledge about cell growth control, Cxs seems to be a
“helper” instead of a master regulator of cell growth control. Hopefully, future studies will bring more
clear-cut information about the real involvement of GJs and Cxs in cancer cell growth [190].
In addition, we have also to consider that exceptions were observed in the consensus supporting
the parallel between GJIC and cell growth control. These exceptions, supported by experimental
observations, led to the hypothesis that Cxs could be protumoral actors when expressed at late stage of
cancer progression. Indeed, from about twenty years ago, it appeared that Cxs could favour migration
and invasion of cancer cells and participate to their dissemination [2,94]. A new wave of data then
confirmed this new assumption that Cxs are actively involved in the late stages of carcinogenesis and
participate to the aggressiveness of solid tumours. Very interestingly, from this more recent domain of
investigation, Cxs were shown to play a role not only on migration and invasion of cancer cells but also
on metastasis development by acting on intravasation, extravasation and dormancy of the metastatic
cells. Within a few years, the Cx cancer statute has been changed then from tumour suppressor to
tumour enhancer. Contrary to what appears at a first glance, this is not contradictory since an inverted
correlation is often observed between cell proliferation and invasion capacity [191].
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As for cell growth control, the molecular mechanisms underlying the involvement of Cxs
in cell migration are not very clear. Once again, Cxs seem to control cell migration either
through channel-dependent or –independent mechanisms. In the first case, the establishment of
heterologous GJIC between cancer cells and cells of the tumour microenvironment may increase
motility (such as glioma cells communicating with astrocytes) and further, helps to intravasation
and extravasation [124–127,192]. When isolated in extracellular matrix, Cxs act on motility through
GJIC-independent mechanisms by its CT domain. This has been particularly studied for Cx43 and
even if the precise molecular events are not elucidated yet, it seems that the CT domain is involved
by interacting with the actin cytoskeleton and helps to manage directional migration of the cancer
cells [193]. Interestingly, such a phenomenon would not be pathological by itself since this process
is present in migrations occurring in normal situations such as embryogenesis (neuron precursors
migrating to the cortex) and leucocyte migration [194–196]. Other data also suggest that Cxs could
be involved in formation of invadopodia and secretion of proteases during invasion process and also
in metastasis targeting [132]. The molecular processes of all these phenomena are far from being to
be elucidated. More data are needed to explain at the molecular level how Cxs can control cancer
cell invasion and metastasis. These data are necessary for targeting Cxs to prevent eventually cancer
invasion. This is of fundamental importance when considering that the majority of cancer deaths are
the consequence of metastasis [1].
To conclude, there are globally sufficient data showing that Cxs are involved in carcinogenesis,
especially in the progression of solid tumours. However, despite these data, the molecular mechanisms
of the Cx involvement in carcinogenesis are not sufficiently elucidated yet. This lack of knowledge
limits to use them as general therapeutical targets for cancer control. Moreover, the multifunctional
sides of Cxs able to act as mediator of GJIC, through their interactome or even as Hcs make difficult to
define their real implication in cancer. In addition, the similarity of Panxs with Cx Hcs adds another
complexity to this area of research since this family of proteins seems to share functions with Cxs
both in cell proliferation control and invasion. Facing this complexity, the only way to decipher the
real impact of Cxs or Panxs in the cancer cell behaviour is to consider their involvement specifically
in particular types of tumours but not globally [190]. One strategy could be by increasing in situ
observations in order to localize precisely Cx/Panx expressions in the complex heterogeneity of specific
human tumours and reveal the possible links of Cx/Panx localizations with the tumour behaviour. In
particular, it could prove definitively the apparently opposed roles of Cxs in cell growth control and
in cancer cell invasion through their differential expression either in the core of the tumour or in its
invasive edges [111]. Therefore, due to uniqueness of the action of subtypes of Cxs and Cx channels on
various types and stages of cancers, therapeutic approaches ought to be developed based on precise
mechanism elucidated with more targeting approaches. This aligns with the current trend of drug
development in treating cancer with precision medicine.
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